Уноси

• A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings. Antibiotics (Basel). (2025)

  В. Баришић, Т. Ковачевић, M. Travar, А. Голић Јелић, П. Ковачевић, Д. Милаковић, Р. Шкрбић, A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings. Antibiotics (Basel)., Antibiotics, 2025

• The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study (2025)

  В. Баришић, Т. Ковачевић, M. Travar, П. Ковачевић, The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study, Antibiotics, 2025

• Early treatment with pyridostigmine alleviates heart failure with preserved ejection fraction (HFpEF) in rats (2026-01)

  Marinković S, Šobot T, Maksimović Ž, Đukanović Đ, Uletilović S, Mandić-Kovačević N, Jovičić S, Matičić M, Gajić Bojić M, Stojmenovski A, Bojanić A, Lončar-Stojiljković D, Škrbić R, Stojiljković M., Early treatment with pyridostigmine alleviates heart failure with preserved ejection fraction (HFpEF) in rats, CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, Vol. 104, No. 1, pp. 1 - 11, Jan, 2026

• EVALUATION OF CHENODEOXYCHOLIC ACID AS A CARDIOPROTECTIVE AGENT IN ISOPRENALINE-INDUCED MYOCARDIAL INJURY (2025-11)

  D. Dukanovic, D. Mihajlovic, Z. Maksimovic, S. Marinkovic, U. Malicevic, S. Uletilovic, N. Mandic-Kovacevic, S. Јоvicic, Z. Bajic, Т. Sobot, M. Mikov, R. Skrbic, EVALUATION OF CHENODEOXYCHOLIC ACID AS A CARDIOPROTECTIVE AGENT IN ISOPRENALINE-INDUCED MYOCARDIAL INJURY, Nov, 2025

• Дијабетесна неуропатија (2023)

  З. Вукојевић, A. Dominović-Kovačević, Дијабетесна неуропатија, Медицински факултет, Универзитет у Бањој Луци, 2023

• Клиничка електромионеурографија (2024)

  A. Dominović-Kovačević, З. Вукојевић, Клиничка електромионеурографија, Медицинки факултет, Универзитет у Бањој Луци, 2024

• Characteristics of Neuropathic Pain and its Impact on Quality of Life in Patients With Diabetic Polyneuropathy (2020)

  З. Вукојевић, A. Dominović-Kovačević, С. Перић, И. Божовић, С. Гргић, И. Баста, Д. Лаврнић, Characteristics of Neuropathic Pain and its Impact on Quality of Life in Patients With Diabetic Polyneuropathy, 2020

• Sensory Paraneoplastic Neuropathy as the First Manifestation of the Small-Cell Lung Carcinoma (2023)

  З. Вукојевић, A. Dominović-Kovačević, С. Гргић, С. Maвија, Sensory Paraneoplastic Neuropathy as the First Manifestation of the Small-Cell Lung Carcinoma, 2023

• Characteristics of Neuropathic Pain in Patients with Diaбetic Peripheral (2024)

  З. Вукојевић, A. Dominović-Kovačević, С. Гргић, С. Мавија, Characteristics of Neuropathic Pain in Patients with Diaбetic Peripheral, 2024

• Lumbar Polydiscopathy or ALS- Diagnostic Challenge: a Case report . (2024)

  З. Вукојевић, A. Dominović-Kovačević, С. Гргић, С. Мавија, Lumbar Polydiscopathy or ALS- Diagnostic Challenge: a Case report ., 2024

• Characteristics of Neuropathic Pain in Patients with Diabetic Peripheral Neuropathy (2025)

  З. Вукојевић, A. Dominović-Kovačević, С. Гргић, S. Mavija, Characteristics of Neuropathic Pain in Patients with Diabetic Peripheral Neuropathy, 2025

• АЛС мултисистемска болест (2026)

  A. Dominović-Kovačević, АЛС мултисистемска болест, 2026

• Uticaj đubrenja na vegetativni razvoj i prinos krompira na području opštine Glamoč (2025-12-05T07:50:57.520Z)

• Vascular comorbidites in patients with multiple sclerosis and their impact on physical disability (2022-05)

  Д. Тадић, С. Гргић, A. Dominović-Kovačević, M. Nazalević Bursac, S. Mavija, В. Ђајић, Vascular comorbidites in patients with multiple sclerosis and their impact on physical disability, Medicinski glasnik Zenica, Vol. 19(2), pp. 166 - 172, May, 2022

• Association between byochemical risk factors for cerebrovascular diseases and clinical phenotype of multiple sclerosis (2025-01)

  Д. Тадић, В. Ђајић, A. Dominović-Kovačević, З. Вукојевић, Б. Злојутро, М. Јандрић, О. Љубоја, Д. Врањеш, М. Гњатић, Association between byochemical risk factors for cerebrovascular diseases and clinical phenotype of multiple sclerosis, Časopis udruženja pulmologa Republike Srpske, Vol. 15(1-2), pp. 170 - 178, Jan, 2025

• 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-labek extension study (ATB200-07) (2024)

  B. Schoser, P. Kishnani, D. Batkovic, B. Byrne, K. Claeys, J. Diaz- Manera, P. Laforet, M. Roberts, A. Toscano, A. Van der Ploeg, J. Castelli, M. Goldman, F. Holdbrook, S. Sitaraman, Y. Wasfi, T. Mozaffar, A. Sebok, A. Pestronk, A. Dominović-Kovačević, A. Khan, B. Koritnik, C. Tard, C. Lindberg, C. Quinn, C. Eldridge, C. Bodkin, D. Reyes-Leiva, D. Hughes, E. Stefanescu, E. Salort-Campana, E. Butler, F. Bouhour, G. Kim, G. Konstantinos-Papadimas, G. Parenti, H. Bartosik-Psujek, H. Kushlaf, H. Akihiro, H. Lau, H. Pedro, H. Andersen, H. Amartino, H. Shiraishi, H. Kobayashi, I. Tarnev, J. Vengoechea, J. Avelar, J. Shin, J. Nevin, J. Cauci, J. Alonso-Perez, J. Janszky, J. Berthy, C. Kornblum, K. Gutschmidt, M. Judit-Molnar, M. Wencel, M. Tarnopolsky, M. Boentert, M. Tchan, M. Freimer, N. Longo, N. Abreu, N. Vidal-Fernandez, O. Musumeci, O. Goker-Alpan, P. Deegan, P. Clemens, R. Roxburgh, R. Henderson, R. Hopkin, S. Sacconi, S. Fecarotta, S. Attarian, S. Wenninger, S. Dearmey, T. Hiwot, T. Burrow, T. Ruck, T. Sawada, V. Laszlo, W. Loscher, Y. Chien, 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-labek extension study (ATB200-07), JOURNAL OF NEUROLOGY, Vol. 271, pp. 2810 - 2823, 2024

• Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient - reported outcome measures in patients with late-onset Pompe disease (2024-11)

  P. Kishnani, B. Byrne, K. Claeys, J. Diaz- Manera, M. Dimachkie, H. Kushlaf, T. Mozaffar, M. Roberts, B. Schoser, N. Hummel, A. Kopiec, F. Holdbrook, S. Shohet, A. Toscano, A. Sebok, A. Pestronk, A. Dominović-Kovačević, A. Khan, B. Koritnik, C. Tard, C. Lindberg, C. Quinn, C. Eldridge, C. Bodkin, D. Reyes-Leiva, D. Hughes, E. Stefanescu, E. Salort-Campana, E. Butler, F. Bouhour, G. Kim, G. Konstantinos-Papadimas, G. Parenti, H. Bartosik-Psujek, H. Akihiro, H. Lau, H. Pedro, H. Andersen, H. Amartino, H. Shiraishi, H. Kobayashi, I. Tarnev, J. Vengoechea, J. Avelar, J. Shin, J. Cauci, J. Alonso-Perez, J. Janszky, J. Berthy, C. Kornblum, K. Gutschmidt, M. Judit-Molnar, M. Wencel, M. Tarnopolsky, M. Tchan, M. Freimer, N. Longo, N. Vidal-Fernandez, O. Musumeci, O. Goker-Alpan, P. Deegan, P. Clemens, R. Roxburgh, R. Henderson, R. Hopkin, S. Sacconi, S. Fecarotta, S. Attarian, S. Wenninger, S. Dearmey, T. Hiwot, T. Burrow, T. Ruck, T. Sawada, V. Laszlo, W. Loscher, Y. Chien, Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient - reported outcome measures in patients with late-onset Pompe disease, Journal of patient - reported outcomes, Vol. 13;8(1):132, Nov, 2024

• Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease(PROPEL): an international randomised,double-blind, parallel-group,phase 3 trial (2021-12)

  B. Schoser, M. Roberts, B. Byrne, S. Sitaraman, H. Jiang, P. Laforet, A. Toscano, J. Castelli, J. Diaz- Manera, M. Goldman, A. Van der Ploeg, D. Batkovic, S. Kuchipudi, T. Mozaffar, P. Kishnani, A. Sebok, A. Pestronk, A. Dominović-Kovačević, A. Khan, B. Koritnik, C. Tard, C. Lindberg, C. Quinn, C. Eldridge, C. Bodkin, D. Reyes-Leiva, D. Hughes, E. Stefanescu, E. Salort-Campana, E. Butler, F. Bouhour, G. Kim, G. Konstantinos-Papadimas, G. Parenti, H. Bartosik-Psujek, H. Kushlaf, H. Akihiro, H. Lau, H. Pedro, H. Andersen, H. Amartino, H. Shiraishi, H. Kobayashi, I. Tarnev, J. Vengoechea, J. Avelar, J. Shin, J. Cauci, J. Alonso-Perez, J. Janszky, J. Berthy, C. Kornblum, K. Gutschmidt, K. Claeys, M. Judit-Molnar, M. Wencel, M. Tarnopolsky, M. Dimachkie, M. Tchan, M. Freimer, N. Longo, N. Vidal-Fernandez, O. Musumeci, O. Goker-Alpan, P. Deegan, P. Clemens, R. Roxburgh, R. Henderson, R. Hopkin, S. Sacconi, S. Fecarotta, S. Attarian, S. Wenninger, S. Dearmey, T. Hiwot, T. Burrow, T. Ruck, T. Sawada, V. Laszlo, W. Loscher, Y. Chien, Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease(PROPEL): an international randomised,double-blind, parallel-group,phase 3 trial, THE LANCET NEUROLOGY, Vol. 20(12), pp. 1027 - 1037, Dec, 2021

• Thyroid dysfunction in patients with multiple sclerosis:prevalence and associated risk factors (2025-12)

  Д. Тадић, С. Гргић, A. Dominović-Kovačević, З. Вукојевић, Г. Малешевић, В. Станковић-Солдат, Thyroid dysfunction in patients with multiple sclerosis:prevalence and associated risk factors, Biomedicinska istraživanja - Časopis Medicinskog fakulteta Foča, Vol. 16(2), pp. 1 - 12, Dec, 2025

• Vascular comorbidities in patient with multiple sclerosis and their impact on physical disability (2022-06)

  Д. Тадић, С. Гргић, A. Dominović-Kovačević, M. Nazalević Bursac, S. Mavija, В. Ђајић, Vascular comorbidities in patient with multiple sclerosis and their impact on physical disability, Časopis udruženja pulmologa Republike Srpske, Vol. 19(2), pp. 166 - 172, Jun, 2022